Investors
Events & presentations
Erik Penser Bank theme day for Life Science Tools 2021
CEO Teodor Aastrup's presentation at Erik Penser Bank's theme day for Life Science Tools (2021-09-16).
An introduction to the how Attana delivers value to its Life Science customers and an update on our progress with Attana Diagnostics.
Q&A with Erik Penser Bank
CEO Teodor Aastrup and Head of Diagnostics Samir Fostock participate in a Q&A session with Erik Penser Bank (2021-08-11).
Småbolagsdagarna 2021
Our presentation at Aktiespararna's "Småbolagsdagarna" (2021-06-10)
CEO Teodor Aastrup gives and introduction to the company and where Attana is heading.
Erik Penser Bank's Bolagsdag 2021
CEO Teodor Aastrup's presentation at Erik Penser Bank's Bolagsdag (2021-06-03).
An introduction to the company and recent updates on our progress with Attana Diagnostics.
Drug Discovery V-Forum 2021
Our presentation at Drug Discovery V-Forum (2021-04-22).
CEO Teodor Aastrup presents the company and Attana's business areas – Life Science and Diagnostics.
Biotech Showcase™ 2021
Our presentation at Biotech Showcase™ (2021-01-11).
CEO Teodor Aastrup presents Attana's two business areas – Attana Research & Development and Attana Diagnostics.
Financial information
Financial reports & calendar
2022-02-24 – Bokslutskommuniké 2021
2021-02-25 – Bokslutskommuniké 2020
2021-05-07 – Årsredovisning 2020
2021-05-07 – Delårsrapport Q1 2021 (jan-mar)
2020-11-27 – Delårsrapport Q3 2020 (jul-sep)
2020-08-18 – Halvårsrapport H1 2020 (jan-jun)
2020-05-08 – Årsredovisning 2019
2019-11-29 – Delårsrapport Q3 2019 (juli-sep)
2019-08-20 – Halvårsrapport H1 2019 (jan-jun)
2019-05-07 – Delårsrapport Q1 2019 (jan-mar)
Memorandums & offerings
Stock information
Attana has issued shares in one class. You can follow the development here.
The share capital in the company is SEK 1,022,813,406, divided into 170,468,901 shares with a quota value of SEK 0.006.
Name: ATANA
ISIN: SE0010547273
Investor relations
Teodor Aastrup – CEO
Tel: +46-8-410 200 00
Email: ir@attana.com
NGM mentor
Eminova Fondkomission AB
Tel: +46-8-684 211 00
Email: adviser@eminova.se
News & press
Attana’s press announcements and news are published via Cision. Attana communicates in Swedish or English. Attana AB is required under the Swedish Securities Market Act to disclose certain information and such information is primarily provided in Swedish on the Swedish news room.
Information related to scientific publications from the company’s customers is primarily provided in English on the English news room.
If you wish to receive all information from Attana we recommend that you subscribe for news written in Swedish and English by visiting the news rooms.
Corporate governance
General meetings
2020-10-26 – Styrelsens redogörelse över väsentliga händelser (9 november)
2020-10-26 – Revisorns yttrande över styrelsens redogörelse (9 november)
2020-10-26 – Fullständiga förslag till emissionen (9 november)
2020-10-21 – Kallelse till extra bolagsstämma (9 november)
2020-10-21 – Notice to attend extraordinary general meeting (November 9)
2020-05-08 – Årsstämma verksamhetsår 2019
Other company documents
Board of Directors
Arne Nabseth (b. 1963)
Chairman since 2015
25 years of experience in the IT industry. Entrepreneurial experience from building PCM Nordic/MAS, Applicon and Qrodo. Previously venture capitalist at Ledstiernan, IT manager at Philips Electronics, KPMG, Bearing Point Silicon Valley and an angel investor.
Teodor Aastrup (b. 1970)
CEO, Co-Founder & Director since 2013
PhD from KTH Royal Institute of Technology and MSc in Material Physics from Uppsala University. Long experience from defining, developing and commercializing business strategies. Previously responsible for chemical analytics at Scania.
Lena Jendeberg (b. 1964)
Director since 2018
PhD from KTH Royal Institute of Technology with 25+ years of experience in the pharmaceutical industry working at Pharmacia, Biovitrum, Sobi, Modus Therapeutics and Wilson Therapeutics. Have developed pharmaceuticals all the way from the pre-clinical phase to improvement of approved products.
Per Aniansson (b. 1966)
Director since 2021
MSc in Engineering Physics from Chalmers University of Technology and an MBA from INSEAD. More than 20 years of experience from Venture Capital and Private Equity investments and responsible for a large number of investments, fund raisings and exits. Previously responsible for medical technology investments at Fouriertransform and currently CFO for Karolinska Development.
Ingemar Kihlström (b. 1952)
Director since 2017
Docent from Uppsala University with 15+ years of pharmaceutical business development at AstraZeneca and Pharmacia. 10+ years of experience in life science corporate finance. Chairman of MedCap, Artimplant, Prolight Diagnostics, Karocell Tissue Engineering and Acromed.